PL222088A1 - - Google Patents

Info

Publication number
PL222088A1
PL222088A1 PL22208880A PL22208880A PL222088A1 PL 222088 A1 PL222088 A1 PL 222088A1 PL 22208880 A PL22208880 A PL 22208880A PL 22208880 A PL22208880 A PL 22208880A PL 222088 A1 PL222088 A1 PL 222088A1
Authority
PL
Poland
Application number
PL22208880A
Other versions
PL129707B1 (en
Original Assignee
Boehringer Mannheim Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim Gmbh filed Critical Boehringer Mannheim Gmbh
Publication of PL222088A1 publication Critical patent/PL222088A1/xx
Publication of PL129707B1 publication Critical patent/PL129707B1/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D203/00Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D203/04Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D203/06Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D203/22Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
PL1980222088A 1979-02-21 1980-02-18 Process for preparing novel n-substituted derivatives of aziridine-2-carboxylic acid PL129707B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19792906603 DE2906603A1 (de) 1979-02-21 1979-02-21 N-substituierte aziridin-2-carbonsaeurederivate, verfahren zu deren herstellung sowie diese substanzen enthaltende arzneimittel

Publications (2)

Publication Number Publication Date
PL222088A1 true PL222088A1 (OSRAM) 1980-12-01
PL129707B1 PL129707B1 (en) 1984-06-30

Family

ID=6063481

Family Applications (1)

Application Number Title Priority Date Filing Date
PL1980222088A PL129707B1 (en) 1979-02-21 1980-02-18 Process for preparing novel n-substituted derivatives of aziridine-2-carboxylic acid

Country Status (19)

Country Link
US (2) US4397848A (OSRAM)
EP (1) EP0014976B1 (OSRAM)
JP (1) JPS55113760A (OSRAM)
AR (1) AR223863A1 (OSRAM)
AT (1) ATE818T1 (OSRAM)
AU (1) AU529982B2 (OSRAM)
CA (1) CA1148962A (OSRAM)
CS (1) CS208798B2 (OSRAM)
DD (1) DD148772A5 (OSRAM)
DE (2) DE2906603A1 (OSRAM)
ES (1) ES488656A1 (OSRAM)
FI (1) FI70702C (OSRAM)
HU (1) HU182801B (OSRAM)
IE (1) IE49267B1 (OSRAM)
IL (1) IL59425A (OSRAM)
PL (1) PL129707B1 (OSRAM)
PT (1) PT70847A (OSRAM)
SU (1) SU1181541A3 (OSRAM)
ZA (1) ZA80902B (OSRAM)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925835A (en) * 1986-05-01 1990-05-15 Sloan-Kettering Institute For Cancer Research Aziridinyl putrescine containing compositions and their uses in treating prostate cancer
JPH07301287A (ja) * 1995-03-23 1995-11-14 Sumitomo Heavy Ind Ltd 制御装置に用いられる内接噛合遊星歯車機構
AU8171498A (en) * 1997-06-27 1999-01-19 Arizona Board Of Regents On Behalf Of The University Of Arizona, The Novel cyanoaziridines for treating cancer
US20030129222A1 (en) * 2000-11-21 2003-07-10 Gabriel Lopez-Berestein Liposomal imexon
CA2431947A1 (en) * 2000-11-21 2002-05-30 Gabriel Lopez-Berestein Composition comprising an imexon or derivatives thereof and lipids
US7011846B2 (en) * 2001-12-21 2006-03-14 Shire Laboratories, Inc. Oral capsule formulation with increased physical stability
US20040005339A1 (en) * 2002-06-28 2004-01-08 Shojaei Amir H. Formulations of fenofibrate and/or fenofibrate derivatives with improved oral bioavailability
SG182004A1 (en) 2003-01-14 2012-07-30 Arena Pharm Inc 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
SI1606282T1 (sl) * 2003-02-24 2009-04-30 Arena Pharm Inc Fenilni in piridilpiperidinski derivati kot modulatorji glukoznega metabolizma
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
PT1756084E (pt) * 2004-06-04 2009-02-17 Arena Pharm Inc Composto seleccionado de compostos de fórmula (i) e seus sais, solvatos, hidratos e n-óxidos farmaceuticamente aceitáveis
MY148521A (en) * 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
DOP2006000010A (es) 2005-01-10 2006-07-31 Arena Pharm Inc Procedimiento para preparar eteres aromáticos
ES2326391T3 (es) * 2005-09-16 2009-10-08 Arena Pharmaceuticals, Inc. Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo.
TW200811140A (en) * 2006-07-06 2008-03-01 Arena Pharm Inc Modulators of metabolism and the treatment of disorders related thereto
TW200811147A (en) * 2006-07-06 2008-03-01 Arena Pharm Inc Modulators of metabolism and the treatment of disorders related thereto
CN103221391B (zh) 2010-01-27 2018-07-06 艾尼纳制药公司 (R)-2-(7-(4-环戊基-3-(三氟甲基)苄基氧基)-1,2,3,4-四氢环戊二烯并[b]吲哚-3-基)乙酸及其盐的制备方法
US10894787B2 (en) 2010-09-22 2021-01-19 Arena Pharmaceuticals, Inc. Modulators of the GPR119 receptor and the treatment of disorders related thereto
KR20230151072A (ko) 2015-01-06 2023-10-31 아레나 파마슈티칼스, 인크. S1p1 수용체와 관련된 상태의 치료 방법
US10301262B2 (en) 2015-06-22 2019-05-28 Arena Pharmaceuticals, Inc. Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compund1) for use in SIPI receptor-associated disorders
JP2020507611A (ja) 2017-02-16 2020-03-12 アリーナ ファーマシューティカルズ, インコーポレイテッド 原発性胆汁性胆管炎の治療のための化合物および方法
KR102859841B1 (ko) 2018-06-06 2025-09-12 아레나 파마슈티칼스, 인크. S1p1 수용체와 관련된 병태의 치료 방법
CN113816887A (zh) * 2021-08-31 2021-12-21 华中科技大学 一种氮杂环丙烷类化合物及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2644820A1 (de) * 1976-10-05 1978-04-06 Boehringer Mannheim Gmbh Cancerostatisch und immunstimulierend wirkende 1-(n-acyl-carbamoyl)-2-cyanaziridine sowie verfahren zur herstellung derselben
DE2731264A1 (de) 1977-07-11 1979-02-01 Boehringer Mannheim Gmbh Neue 1-acyl-2-cyanaziridine, verfahren zu deren herstellung und diese verbindungen enthaltende pharmazeutische zubereitungen

Also Published As

Publication number Publication date
CA1148962A (en) 1983-06-28
ATE818T1 (de) 1982-04-15
DD148772A5 (de) 1981-06-10
SU1181541A3 (ru) 1985-09-23
PL129707B1 (en) 1984-06-30
ZA80902B (en) 1981-03-25
CS208798B2 (en) 1981-09-15
IE49267B1 (en) 1985-09-04
FI70702C (fi) 1986-10-06
FI800510A7 (fi) 1980-08-22
EP0014976A1 (de) 1980-09-03
ES488656A1 (es) 1980-09-16
HU182801B (en) 1984-03-28
FI70702B (fi) 1986-06-26
IL59425A (en) 1984-05-31
JPH0150700B2 (OSRAM) 1989-10-31
IL59425A0 (en) 1980-05-30
US4517183A (en) 1985-05-14
AU529982B2 (en) 1983-06-30
AU5564980A (en) 1980-08-28
EP0014976B1 (de) 1982-04-07
IE800327L (en) 1980-08-21
US4397848A (en) 1983-08-09
JPS55113760A (en) 1980-09-02
AR223863A1 (es) 1981-09-30
DE3060268D1 (en) 1982-05-19
PT70847A (de) 1980-03-01
DE2906603A1 (de) 1980-09-04

Similar Documents

Publication Publication Date Title
BR8002583A (OSRAM)
BR8006808A (OSRAM)
AT364253B (OSRAM)
AU78386S (OSRAM)
AU79559S (OSRAM)
AU77669S (OSRAM)
AU78389S (OSRAM)
AU78390S (OSRAM)
AU78391S (OSRAM)
AU78569S (OSRAM)
AU79200S (OSRAM)
AU79557S (OSRAM)
AU78385S (OSRAM)
AU79826S (OSRAM)
AU78271S (OSRAM)
AU78270S (OSRAM)
AU79918S (OSRAM)
AU79950S (OSRAM)
AU80228S (OSRAM)
BR5901094U (OSRAM)
AU79558S (OSRAM)
AU77763S (OSRAM)
BG28434A1 (OSRAM)
BG28729A1 (OSRAM)
BG28229A1 (OSRAM)